

UPDATE ON MPOX

BOARD MEETING

Emanuele Capobianco

24-25 July 2025, Geneva, Switzerland



Context: mpox outbreak and response

Active outbreak continues to affect multiple countries in the African region (with DRC the epicentre), with exported cases reported globally



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: World Health Organization
Map Production: WHO Health Emergencies Programme
© WHO 2025. All rights reserved.

With continental and global public health emergency declarations extensions until Sept 2025, Gavi continues to support vaccine response as part of cross partner efforts

- **Progress in access to vaccines and vaccine roll-out:**
 - Seven countries vaccinating with two more expected
- **Country challenges:** Global and domestic including conflict and resource limitations in health systems, surveillance and testing
- **Gavi engaged in learning efforts:**
 - Both internal & cross-partner led learning and monitoring of progress and results
 - Collaborating with partners to integrate learnings

2024-2025 numbers in Africa*

Total confirmed cases	44,776
Total confirmed deaths	166

*Data source: World Health Organisation. Confirmed cases and deaths only. Data as of 06 July 2025.

Contribution to mpox response: Gavi is to date the largest provider of MVA-BN mpox vaccines

Rapid access to financing, vaccines and delivery support

Rapid response:

- **First Response Fund:** Steering Committee approved drawdown 30 days post-PHEIC
- **Rapid reprogramming of funding**


Secure and deliver vaccines:

- **Securing supply:** Gavi APA for 500,000 MVA-BN signed 35 days post-PHEIC and facilitate dose donations
- **All 500,000 APA doses and >245,000 Gavi facilitated doses delivered** to 9 countries

Supporting vaccine roll-out:

- **Delivery funding:** >US\$ 9.5 million approved or disbursed to date for delivery support funded by Gavi
- **Vaccination:** 7 countries have administered >840,000 doses to date, with Gavi funding supporting roll-out

Mpox vaccine deliveries in Africa



Data as of 27 June 2025

Global mpox stockpile for outbreak response: conditions for a final board approval have now been met



Investment conditions

A global mpox stockpile was approved in-principle through the VIS 2024, contingent on conditions, of which key ones have now been met:

- ✓ Outcomes of regulatory and technical reviews (WHO PQ/EUL)
- ✓ WHO/SAGE recommendation



Updated analysis and learning agenda

- Reflecting consultations, lessons learned, revised assumptions, and financial implications
- Results from a Board-approved learning agenda are now available - with estimates of stockpile sizes and the associated health and economic impact



Final Board approval required

- To ensure a long-term solution and secure funding for Gavi 6.0
- Initiate programme planning & design for its operationalisation with partners
- Contingent on financial resources being made available for the Gavi 6.0 strategic period

The proposed global mpox stockpile is intended as a long-term mechanism ensuring rapid access to mpox vaccines



Total doses: 500,000 to be procured in Gavi 6.0 for outbreak response. Based on Gavi's Board's in-principle decision. According to modelled estimates from the learning agenda, expected to respond to 44–52% of mpox outbreaks in Gavi-eligible countries.



A step forward: Part of a holistic response to complement efforts by countries and other organisations.



Composition: Any WHO-prequalified or emergency use-listed vaccine meeting stockpile mechanism requirements.




Vaccination strategy: To follow WHO/SAGE normative guidance for outbreak response (including dose-sparing strategies in supply constrained outbreak scenario). Operational support tailored to each country's context given the expectation of specific delivery requirements.



Management: Expected by the ICG or a similar mechanism, with tendering and procurement managed by UNICEF. Explore collaboration with additional partners (i.e. Africa CDC) and any national/regional stockpiling mechanisms to enable a coordinated response.

A Gavi-supported 6.0 Global Mpox Stockpile could launch in H2 2026 at the earliest – timeline as of July 2025



Milestones:

- **Gavi Board decision** – July 2025
- **ICG Governance Oversight Committee decision** – Expected by September 2025
- **Programme planning and co-design with ICG (UNICEF, MSF, IFRC, WHO) & partners** – H2 2025 & H1 2026
- **Programme & global stockpile launch** – H2 2026

Recommendation

The Gavi Alliance Programme and Policy Committee **recommended** to the Gavi Alliance Board that, contingent on financial resources being made available for the Gavi 6.0 strategic period, it:

- a) **Approve** the opening of a funding window for the establishment of an mpox programme through an emergency stockpile for i) reactive vaccination in an outbreak setting and ii) potential repurposing of stockpile doses at risk of expiring for preventive vaccination in at-risk groups contingent on SAGE recommendations;
- b) **Note** ongoing efforts to address data gaps, including the stockpile sizing learning agenda and the collaborative design of the global stockpile, shaping the final programme and financial estimates.

Thank you